A TRH analog (DN-1417): Effects on local cerebral glucose utilization in conscious and pentobarbitalized rats determined by the autoradiographic 2-deoxy-(14C)glucose method.
スポンサーリンク
概要
- 論文の詳細を見る
Effects of a TRH (thyrotropin-releasing hormone) analog, DN-1417 (γ-butyrolactone-γ-carbonyl-L-histidyl-L-prolinamide citrate), with regard to the rate of local cerebral glucose utilization (LCGU) were assessed using the autoradiographic 2-deoxy-D-[<SUP>14</SUP>C]glucose method to clarify the possible sites of action in conscious and pentobarbitalized rats. DN-1417 (0.5-5 mg/kg, i.v.) significantly shortened the pentobarbital-induced sleeping time in a dose dependent manner, and this effect of DN-1417 was reduced by intracerebroventricular (i.c.v.) pretreatment with atropine methylbromide (20 μg). DN-1417 (5 mg/kg, i.v.) by itself slightly increased the LCGU in the thalamus dorsomedial nucleus and mammillary body and significantly increased it in the septal nucleus. Pentobarbital (30 mg/kg, i.v.) alone produced a marked and diffuse reduction in LCGU throughout the brain at a rate of about 46% of the control. DN-1417 (5 mg/kg, i.v.) markedly reversed the reduction of LCGU induced by pentobarbital. The antagonistic effect of DN-1417 in LCGU was about twice as potent as that of TRH. Locally, significant reversal effects by DN-1417 were observed in the hypothalamus, septal nucleus, hippocampus, mammillary body, thalamus dorsomedial nucleus, caudate-putamen, nucleus accumbens, pontine gray matter and so on. These actions of DN-1417 were almost completely abolished in all areas except for the visual cortex under the condition of pretreatment with atropine methylbromide (20 μg, i.c.v.). On the other hand, pimozide (1 mg/kg, i.p.) augmented the actions of DN-1417. Thus, DN-1417 seems to act on the level of consciousness via a reticulo-thalamo-cortical system, and reverses the LCGU reduction induced by pentobarbital via a cholinergic mechanism. The hypothalamus appears to be a crucial site in mediation of the antagonistic action of DN-1417 on pentobarbital.
- 公益社団法人 日本薬理学会の論文
著者
-
Miyamoto Masaomi
Central Research Division Takeda Chemical Industries Ltd.
-
NARUMI SHIGEHIKO
Central Research Division, Takeda Chemical Industries, Ltd.
-
Nagawa Yuji
Central Research Division Takeda Chemical Industries Ltd.
-
Nagai Yasuo
Central Research Division Takeda Chemical Industries Ltd.
-
SAJI Yoshiaki
Central Research Division, Takeda Chemical Industries, Ltd.
-
SAJI YOSHIAKI
Central Research Division, Takeda Chemical Industries Ltd.
関連論文
- MECHANISM OF ANTIPENTOBARBITAL ACTION OF THYROTROPIN-RELEASING HORMONE (TRH)
- THYROTROPIN-RELEASING HORMONE: HYPERACTIVITY AND MESOLIMBIC DOPAMINE SYSTEM IN RATS
- BLOOD LEVEL AND BRAIN DISTRIBUTION OF THYROTROPIN-RELEASING HORMONE (TRH) DETERMINED BY RADIOIMMUNOASSAY AFTER INTRAVENOUS ADMINISTRATION IN RATS
- A TRH analog (DN-1417): Effects on local cerebral glucose utilization in conscious and pentobarbitalized rats determined by the autoradiographic 2-deoxy-(14C)glucose method.
- Increase in rat regional brain cyclic nucleotides by thyrotropin-releasing hormone (TRH) and its analog DN-1417.
- Effects of idebenone (CV-2619) on metabolism of monoamines, especially serotonin, in the brain of normal rats and rats with cerebral ischemia.
- Effects of TRH and an Analog, DN-1417 on the Activities of Single Neurons in the Nucleus Accumbens, Cerebral Cortex and Caudate-putamen of Rats
- Effects of idebenone (CV-2619) on endogenous monoamine release and cyclic AMP formation in diencephalon slices from rats.
- Pharmacologic characterization of a novel non-benzodiazepine selective anxiolytic, DN-2327.
- Beneficial effect of idebenone (CV-2619) on cerebral ischemia-induced amnesia in rats.
- A possible mechanism of action of thyrotropin-releasing hormone (TRH) and its analog DN-1417 on the release of dopamine from the nucleus accumbens and striatum in rats.
- In vivo electrochemical detection of 5-hydroxyindoles in the dorsal hippocampus of anesthetized rats treated with idebenone (CV-2619).